REFERENCES
1. Beal EW, Tumin D, Moris D, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7:270-6.
2. Ma B, Meng H, Tian Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer 2020;20:318.
3. Akita M, Fujikura K, Ajiki T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol 2017;30:986-97.
4. Chapman MH, Thorburn D, Hirschfield GM, et al. British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019;68:1356-78.
5. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020;72:95-103.
6. European Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol 2023;79:181-208.
7. Kim YY, Yeom SK, Shin H, et al. Clinical staging of mass-forming intrahepatic cholangiocarcinoma: computed tomography versus magnetic resonance imaging. Hepatol Commun 2021;5:2009-18.
8. Kim TH, Kim H, Joo I, Lee JM. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol 2020;21:1115-25.
9. Malikowski T, Levy MJ, Gleeson FC, et al. Endoscopic ultrasound/fine needle aspiration is effective for lymph node staging in patients with cholangiocarcinoma. Hepatology 2020;72:940-8.
10. Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The clinical management of cholangiocarcinoma in the united states and europe: a comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol 2021;28:2660-74.
11. Cholangiocarcinoma Working Group. Italian clinical practice guidelines on cholangiocarcinoma - part ii: treatment. Dig Liver Dis 2020;52:1430-42.
12. Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:541-65.
13. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014;110:163-70.
14. Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020;72:364-77.
15. Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post Hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst 2020;112:200-10.
16. Sha M, Jeong S, Xia Q. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl 2020;26:1202-3.
17. Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016;64:1178-88.
18. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014;25:391-8.
19. Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 2022;7:522-32.
20. Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves! Cancer Treat Res Commun 2021;27:100335.
21. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6:60-7.
22. Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 2020;11:4534-41.
23. Gupta AN, Gordon AC, Gabr A, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol 2022;45:1117-28.
24. Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 Radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 2020;43:1305-14.
25. Jonczyk M, Collettini F, Schnapauff D, et al. Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (<4 cm) and large (>4 cm) tumors. Anticancer Res 2018;38:5843-52.
26. Owen M, Makary MS, Beal EW. Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers 2023;15:2384.
27. Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:590-6.
28. Brandi G, Rizzo A, Dall'Olio FG, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperthermia 2020;37:479-85.
29. Xiang X, Hu D, Jin Z, Liu P, Lin H. Radiofrequency ablation vs. surgical resection for small early-stage primary intrahepatic cholangiocarcinoma. Front Oncol 2020;10:540662.
30. Bale R, Schullian P, Haidu M, Widmann G. [Stereotactic radiofrequency ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection]. Wien Med Wochenschr 2013;163:128-31.
31. Haidu M, Dobrozemsky G, Schullian P, et al. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol 2012;35:1074-82.
32. Sweeney J, Parikh N, El-Haddad G, Kis B. Ablation of intrahepatic cholangiocarcinoma. Semin Intervent Radiol 2019;36:298-302.
33. Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010;21:S192-203.
34. Lee SM, Ko HK, Shin JH, Kim JH, Chu HH. Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival. Diagn Interv Radiol 2020;26:45-52.
35. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:2-6.
36. Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015;26:943-8.
37. Ahmed M, Solbiati L, Brace CL, et al. International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 2014;273:241-60.
39. Chu HH, Kim JH, Shin YM, Won HJ, Kim PN. Percutaneous radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection: multivariable analysis of factors predicting survival outcomes. AJR Am J Roentgenol 2021;217:426-32.
40. Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011;80:e221-5.
41. Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011;196:W205-9.
42. Carrafiello G, Laganà D, Cotta E, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol 2010;33:835-9.
43. Butros SR, Shenoy-Bhangle A, Mueller PR, Arellano RS. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014;38:490-4.
44. Yu MA, Liang P, Yu XL, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol 2011;80:548-52.
45. Wang X, Liang P, Yu J, et al. Contrast-enhanced ultrasound features predict the prognosis of percutaneous microwave ablation of intrahepatic cholangiocarcinoma. Br J Radiol 2022;95:20211379.
46. Ni JY, An C, Zhang TQ, Huang ZM, Jiang XY, Huang JH. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperthermia 2019;36:328-36.
47. Yang H, Cheng Z, Han Z, et al. Assessment of the outcomes of intrahepatic cholangiocarcinoma after ultrasound-guided percutaneous microwave ablation based on albumin-bilirubin grade. Cardiovasc Inter Rad 2021;44:261-70.
48. Zhang K, Yu J, Yu X, et al. Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma. Int J Hyperthermia 2018;34:292-7.
49. Giorgio A, Gatti P, Montesarchio L, et al. Intrahepatic cholangiocarcinoma and thermal ablation: long-term results of an italian retrospective multicenter study. J Clin Transl Hepatol 2019;7:287-92.
50. Zhang SJ, Hu P, Wang N, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013;20:3596-602.
51. Xu C, Li L, Xu W, et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019;36:350-7.
52. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158-71.
53. Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol 2020;30:2463-72.
54. Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology Sans Frontières meeting 2013. Eur Radiol 2015;25:3438-54.
55. Lucatelli P, Argirò R, Crocetti L, et al. Percutaneous thermal segmentectomy: proof of concept. Cardiovasc Intervent Radiol 2022;45:665-76.
56. Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol 2010;75:32-6.
57. Ortler M, Unterhofer C, Bauer R, Dobesberger J, Trinka E, Bale R. Flexibility of head positioning and head fixation provided by a novel system for non-invasive maxillary fixation and frameless stereotaxy: technical note. Minim Invasive Neurosurg 2009;52:144-8.
58. Freysinger W, Gunkel AR, Bale R, et al. Three-dimensional navigation in otorhinolaryngological surgery with the viewing wand. Ann Otol Rhinol Laryngol 1998;107:953-8.
59. Bale R, Widmann G. Navigated CT-guided interventions. Minim Invasive Ther Allied Technol 2007;16:196-204.
60. Bale R, Widmann G, Jaschke W. Stereotaxy and robotics for ablation - toy or tool? Radiologe 2012;52:56-62.
61. Kettenbach J, Kara L, Toporek G, Fuerst M, Kronreif G. A robotic needle-positioning and guidance system for CT-guided puncture: ex vivo results. Minim Invasive Ther Allied Technol 2014;23:271-8.
62. Schaible J, Pregler B, Verloh N, et al. Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system. Radiol Oncol 2020;54:295-300.
63. Scharll Y, Letrari S, Laimer G, Schullian P, Bale R. Puncture accuracy of an optical tracked robotic aiming device-a phantom study. Eur Radiol 2022;32:6769-76.
64. Kim-Fuchs C, Candinas D, Lachenmayer A. The role of conventional and stereotactic microwave ablation for intrahepatic cholangiocarcinoma. J Clin Med 2021;10:2963.
65. Schullian P, Putzer D, Eberle G, Laimer G, Bale R. Simultaneous Stereotactic radiofrequency ablation of multiple (≥ 4) liver tumors: feasibility, safety, and efficacy. J Vasc Interv Radiol 2020;31:943-52.
66. Bale R, Widmann G, Haidu M. Stereotactic radiofrequency ablation. Cardiovasc Inter Rad 2011;34:852-6.
67. Schullian P, Johnston EW, Putzer D, Eberle G, Laimer G, Bale R. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors. Sci Rep 2020;10:1618.
68. Schullian P, Johnston E, Laimer G, et al. Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence. HPB 2022;24:1044-54.
69. Schullian P, Laimer G, Putzer D, et al. Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection. Eur J Surg Oncol 2020;46:1503-9.
70. Bale R, Schullian P, Eberle G, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers. Hepatology 2019;70:840-50.
71. Schullian P, Johnston EW, Putzer D, Eberle G, Laimer G, Bale R. Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study. Int J Hyperthermia 2019;36:876-85.
72. Bale R, Widmann G, Schullian P, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol 2012;22:930-7.
73. Schullian P, Johnston E, Laimer G, et al. Stereotactic radiofrequency ablation of breast cancer liver metastases: short- and long-term results with predicting factors for survival. Cardiovasc Intervent Radiol 2021;44:1184-93.
74. Putzer D, Schullian P, Bale R. Locoregional ablative treatment of melanoma metastases. Int J Hyperthermia 2019;36:59-63.
75. Schullian P, Johnston EW, Putzer D, et al. Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection. Eur J Surg Oncol 2021;47:866-73.
76. Laimer G, Jaschke N, Gottardis M, et al. Stereotactic radiofrequency ablation of an unresectable intrahepatic cholangiocarcinoma (ICC): transforming an aggressive disease into a chronic condition. Cardiovasc Intervent Radiol 2020;43:791-6.
77. Braunwarth E, Schullian P, Kummann M, et al. Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-stereotactic radiofrequency ablation as a valuable addition to hepatic resection. PLoS One 2022;17:e0261136.
78. Bale R, Schullian P, Alzaga A. Narrative review of 3D navigated stereotactic liver ablation-do we still need a minimally invasive liver surgeon? Laparosc Surg 2021;5.
79. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-5.
80. Sposito C, Ratti F, Cucchetti A, et al. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol 2023;78:356-63.
81. Koerkamp BG, Clavien PA, Polak WG. Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes? J Hepatol 2023;78:235-7.
